A high throughput screen identifies benzoquinoline compounds as inhibitors of Ebola virus replication

Priya Luthra, Jue Liang, Colette A. Pietzsch, Sudip Khadka, Megan R. Edwards, Shuguang Wei, Sampriti De, Bruce Posner, Alexander Bukreyev, Joseph M. Ready, Christopher F. Basler

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Ebola virus (EBOV) is an enveloped negative-sense, single-stranded RNA virus of the filovirus family that causes severe disease in humans. Approved therapies for EBOV disease are lacking. EBOV RNA synthesis is carried out by a virus-encoded complex with RNA-dependent RNA polymerase activity that is required for viral propagation. This complex and its activities are therefore potential antiviral targets. To identify potential lead inhibitors of EBOV RNA synthesis, a library of small molecule compounds was screened against a previously established assay of EBOV RNA synthesis, the EBOV minigenome assay (MGA), in 384 well microplate format. The screen identified 56 hits that inhibited EBOV MGA activity by more than 70% while exhibiting less than 20% cell cytotoxicity. Inhibitory chemical scaffolds included angelicin derivatives, derivatives of the antiviral compound GSK983 and benzoquinolines. Structure-activity relationship (SAR) studies of the benzoquinoline scaffold produced ∼50 analogs and led to identification of an optimized compound, SW456, with a submicromolar IC50 in the EBOV MGA and antiviral activity against infectious EBOV in cell culture. The compound was also active against a MGA for another deadly filovirus, Marburg virus. It also exhibited antiviral activity towards a negative-sense RNA virus from the rhabdovirus family, vesicular stomatitis virus, and a positive-sense RNA virus, Zika virus. Overall, these data demonstrate the potential of the EBOV MGA to identify anti-EBOV compounds and identifies the benzoquinoline series as a broad-spectrum antiviral lead.

Original languageEnglish (US)
Pages (from-to)193-201
Number of pages9
JournalAntiviral Research
Volume150
DOIs
StatePublished - Feb 1 2018

Fingerprint

Ebolavirus
Virus Replication
Antiviral Agents
RNA Viruses
RNA
Ebola Hemorrhagic Fever
Marburgvirus
Rhabdoviridae
Small Molecule Libraries
Viruses
RNA Replicase
Vesicular Stomatitis
Structure-Activity Relationship
Inhibitory Concentration 50
Cell Culture Techniques

Keywords

  • Antiviral
  • Ebola virus
  • Filovirus
  • Marburg virus
  • Vesicular stomatitis virus
  • Zika virus

ASJC Scopus subject areas

  • Pharmacology
  • Virology

Cite this

Luthra, P., Liang, J., Pietzsch, C. A., Khadka, S., Edwards, M. R., Wei, S., ... Basler, C. F. (2018). A high throughput screen identifies benzoquinoline compounds as inhibitors of Ebola virus replication. Antiviral Research, 150, 193-201. https://doi.org/10.1016/j.antiviral.2017.12.019

A high throughput screen identifies benzoquinoline compounds as inhibitors of Ebola virus replication. / Luthra, Priya; Liang, Jue; Pietzsch, Colette A.; Khadka, Sudip; Edwards, Megan R.; Wei, Shuguang; De, Sampriti; Posner, Bruce; Bukreyev, Alexander; Ready, Joseph M.; Basler, Christopher F.

In: Antiviral Research, Vol. 150, 01.02.2018, p. 193-201.

Research output: Contribution to journalArticle

Luthra, P, Liang, J, Pietzsch, CA, Khadka, S, Edwards, MR, Wei, S, De, S, Posner, B, Bukreyev, A, Ready, JM & Basler, CF 2018, 'A high throughput screen identifies benzoquinoline compounds as inhibitors of Ebola virus replication', Antiviral Research, vol. 150, pp. 193-201. https://doi.org/10.1016/j.antiviral.2017.12.019
Luthra, Priya ; Liang, Jue ; Pietzsch, Colette A. ; Khadka, Sudip ; Edwards, Megan R. ; Wei, Shuguang ; De, Sampriti ; Posner, Bruce ; Bukreyev, Alexander ; Ready, Joseph M. ; Basler, Christopher F. / A high throughput screen identifies benzoquinoline compounds as inhibitors of Ebola virus replication. In: Antiviral Research. 2018 ; Vol. 150. pp. 193-201.
@article{388b79dd726f4313ba10075e70dbb812,
title = "A high throughput screen identifies benzoquinoline compounds as inhibitors of Ebola virus replication",
abstract = "Ebola virus (EBOV) is an enveloped negative-sense, single-stranded RNA virus of the filovirus family that causes severe disease in humans. Approved therapies for EBOV disease are lacking. EBOV RNA synthesis is carried out by a virus-encoded complex with RNA-dependent RNA polymerase activity that is required for viral propagation. This complex and its activities are therefore potential antiviral targets. To identify potential lead inhibitors of EBOV RNA synthesis, a library of small molecule compounds was screened against a previously established assay of EBOV RNA synthesis, the EBOV minigenome assay (MGA), in 384 well microplate format. The screen identified 56 hits that inhibited EBOV MGA activity by more than 70{\%} while exhibiting less than 20{\%} cell cytotoxicity. Inhibitory chemical scaffolds included angelicin derivatives, derivatives of the antiviral compound GSK983 and benzoquinolines. Structure-activity relationship (SAR) studies of the benzoquinoline scaffold produced ∼50 analogs and led to identification of an optimized compound, SW456, with a submicromolar IC50 in the EBOV MGA and antiviral activity against infectious EBOV in cell culture. The compound was also active against a MGA for another deadly filovirus, Marburg virus. It also exhibited antiviral activity towards a negative-sense RNA virus from the rhabdovirus family, vesicular stomatitis virus, and a positive-sense RNA virus, Zika virus. Overall, these data demonstrate the potential of the EBOV MGA to identify anti-EBOV compounds and identifies the benzoquinoline series as a broad-spectrum antiviral lead.",
keywords = "Antiviral, Ebola virus, Filovirus, Marburg virus, Vesicular stomatitis virus, Zika virus",
author = "Priya Luthra and Jue Liang and Pietzsch, {Colette A.} and Sudip Khadka and Edwards, {Megan R.} and Shuguang Wei and Sampriti De and Bruce Posner and Alexander Bukreyev and Ready, {Joseph M.} and Basler, {Christopher F.}",
year = "2018",
month = "2",
day = "1",
doi = "10.1016/j.antiviral.2017.12.019",
language = "English (US)",
volume = "150",
pages = "193--201",
journal = "Antiviral Research",
issn = "0166-3542",
publisher = "Elsevier",

}

TY - JOUR

T1 - A high throughput screen identifies benzoquinoline compounds as inhibitors of Ebola virus replication

AU - Luthra, Priya

AU - Liang, Jue

AU - Pietzsch, Colette A.

AU - Khadka, Sudip

AU - Edwards, Megan R.

AU - Wei, Shuguang

AU - De, Sampriti

AU - Posner, Bruce

AU - Bukreyev, Alexander

AU - Ready, Joseph M.

AU - Basler, Christopher F.

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Ebola virus (EBOV) is an enveloped negative-sense, single-stranded RNA virus of the filovirus family that causes severe disease in humans. Approved therapies for EBOV disease are lacking. EBOV RNA synthesis is carried out by a virus-encoded complex with RNA-dependent RNA polymerase activity that is required for viral propagation. This complex and its activities are therefore potential antiviral targets. To identify potential lead inhibitors of EBOV RNA synthesis, a library of small molecule compounds was screened against a previously established assay of EBOV RNA synthesis, the EBOV minigenome assay (MGA), in 384 well microplate format. The screen identified 56 hits that inhibited EBOV MGA activity by more than 70% while exhibiting less than 20% cell cytotoxicity. Inhibitory chemical scaffolds included angelicin derivatives, derivatives of the antiviral compound GSK983 and benzoquinolines. Structure-activity relationship (SAR) studies of the benzoquinoline scaffold produced ∼50 analogs and led to identification of an optimized compound, SW456, with a submicromolar IC50 in the EBOV MGA and antiviral activity against infectious EBOV in cell culture. The compound was also active against a MGA for another deadly filovirus, Marburg virus. It also exhibited antiviral activity towards a negative-sense RNA virus from the rhabdovirus family, vesicular stomatitis virus, and a positive-sense RNA virus, Zika virus. Overall, these data demonstrate the potential of the EBOV MGA to identify anti-EBOV compounds and identifies the benzoquinoline series as a broad-spectrum antiviral lead.

AB - Ebola virus (EBOV) is an enveloped negative-sense, single-stranded RNA virus of the filovirus family that causes severe disease in humans. Approved therapies for EBOV disease are lacking. EBOV RNA synthesis is carried out by a virus-encoded complex with RNA-dependent RNA polymerase activity that is required for viral propagation. This complex and its activities are therefore potential antiviral targets. To identify potential lead inhibitors of EBOV RNA synthesis, a library of small molecule compounds was screened against a previously established assay of EBOV RNA synthesis, the EBOV minigenome assay (MGA), in 384 well microplate format. The screen identified 56 hits that inhibited EBOV MGA activity by more than 70% while exhibiting less than 20% cell cytotoxicity. Inhibitory chemical scaffolds included angelicin derivatives, derivatives of the antiviral compound GSK983 and benzoquinolines. Structure-activity relationship (SAR) studies of the benzoquinoline scaffold produced ∼50 analogs and led to identification of an optimized compound, SW456, with a submicromolar IC50 in the EBOV MGA and antiviral activity against infectious EBOV in cell culture. The compound was also active against a MGA for another deadly filovirus, Marburg virus. It also exhibited antiviral activity towards a negative-sense RNA virus from the rhabdovirus family, vesicular stomatitis virus, and a positive-sense RNA virus, Zika virus. Overall, these data demonstrate the potential of the EBOV MGA to identify anti-EBOV compounds and identifies the benzoquinoline series as a broad-spectrum antiviral lead.

KW - Antiviral

KW - Ebola virus

KW - Filovirus

KW - Marburg virus

KW - Vesicular stomatitis virus

KW - Zika virus

UR - http://www.scopus.com/inward/record.url?scp=85040009341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040009341&partnerID=8YFLogxK

U2 - 10.1016/j.antiviral.2017.12.019

DO - 10.1016/j.antiviral.2017.12.019

M3 - Article

C2 - 29294299

AN - SCOPUS:85040009341

VL - 150

SP - 193

EP - 201

JO - Antiviral Research

JF - Antiviral Research

SN - 0166-3542

ER -